期刊名称：CNS NEUROSCIENCE & THERAPEUTICS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
CNS Neuroscience & Therapeutics (formerly CNS Drug Reviews) publishes original research papers, timely reviews and reports of novel findings of therapeutic relevance. The journal focuses on the neuroscience, phenomenology and pathophysiology, as well as pharmacologic and psychosocial therapeutics, of psychiatric and related disorders.
Indexed / Abstracted in
Academic Search (EBSCO)
BIOSIS Preview (Thomson ISI)
BIOSIS(Thomson ISI)
CAS: Chemical Abstracts Service (CAS)
Current Abstracts (EBSCO)
EMBASE/Excerpta Medica (Elsevier)
Index Medicus/MEDLINE (NLM)
Journal Citation Reports/Science Edition (Thomson ISI)
Neuroscience Citation Index(Thomson ISI)
Psychological Abstracts/PsycINFO (APA)
Science Citation Index Expanded (also known as SciSearch)
SCOPUS (Elsevier)
Instructions to Authors
CNS Neuroscience & Therapeutics (formerly CNS Drug Reviews) provides a medium for publication of original research papers, timely reviews and reports of novel findings of therapeutic relevance. The journal focuses on the neuroscience, phenomenology and pathophysiology, as well as pharmacologic and psychosocial therapeutics, of psychiatric and related disorders. Manuscripts should be submitted online via ScholarOne Manuscripts (formerly known as Manuscript Central). Full instructions and support are available on the site and a user ID and password can be obtained on the first visit. For technical support please dial +1 434 817 2040 ext. 167, or via the 'Get Help Now' link in the top right-hand corner of the login screen. If you cannot submit online, please contact the Editorial Office.
Standards. Materials should comply with the ICMJE Uniform Requirements. Manuscripts reporting randomised trials should follow CONSORT guidelines; manuscripts reporting diagnostic accuracy studies should follow STARD guidelines; manuscripts reporting meta-analyses should follow QUOROM guidelines; manuscripts reporting epidemiological studies should follow STROBE guidelines.
Suitability. Your cover letter should explain why your manuscript is suitable for publication in CNS Neuroscience & Therapeutics.
Title. Concise and informative title (read Optimizing for Search Engines).
Authors. Names department(s) and institution(s) of all authors. (In online submission system, confirm that all listed authors meet ICMJE authorship criteria and that nobody who qualifies for authorship has been excluded. Credit for authorship should be based on: [1] substantial contributions to research design, or the acquisition, analysis or interpretation of data; [2] drafting the paper or revising it critically; [3] approval of the submitted and final versions. Authors should meet all three criteria.)
Corresponding author. Name, address, email address, telephone and fax numbers. (Corresponding author should take responsibility for communicating with all other authors and getting their approval for the final version to be published. During online submission corresponding authors can nominate an individual, who may or may not be an author, to assist them with administration of the publication process.)
Author contributions. Recommendation: Include a short description of each authors' contribution immediately before your references. (Examples of categories for authors' contributions: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article, Statistics, Funding secured by, Data collection, Other.)
Access to data. You will be asked during online submission to confirm that authors had access to the study data that support the publication.
Research papers. Your manuscript text should not exceed 4,000 words, with a structured abstract (e.g. Aims, Methods, Results, Discussion, Conclusion) of no more than 250 words, a maximum of 5 tables and/or figures, and up to 100 references. Manuscripts that do not meet these criteria will be returned to the authors for revision prior to formal consideration.
Review papers. Your manuscript text should not exceed 5,000 words, with a structured abstract (e.g. Background, Methods, Results, Conclusion) of no more than 250 words, a maximum of 5 tables and/or figures, and up to 100 references. Manuscripts that do not meet these criteria will be returned to the authors for revision prior to formal consideration.
Funding. Financial support for the study or the manuscript must be disclosed, regardless of its source, including a short description of involvement of the funder in study design, data collection, data analysis, manuscript preparation and/or publication decisions. If none, state "none".
Acknowledgements. Nonfinancial support (e.g. donations of drugs or devices) and individuals who contributed to the study or the manuscript but do not quality as authors must be acknowledged. If none, state "none".
Disclosures. Each author must disclose all financial relationships for the previous 12 months, whether or not they are related to the subject of the paper. This should include equity ownership, profit-sharing agreements, royalties, patents, and grants. Income from pharmaceutical companies should be specified by type, e.g. speaker's honoraria, expenses, grants, etc. Authors do not need to report the sums concerned. If none, state "none".
Prior Publication. You will be asked during online submission to confirm that the submitted work is not published, in press or currently being considered for publication elsewhere. (Abstracts, presentations at scientific meetings and clinical trial data posting should be indicated in your cover letter. Publication of abstracts, presentations at scientific meetings and subsequent press coverage will not jeopardize full publication in CNS Neuroscience & Therapeutics. Posting of clinical trials results in databases [data without interpretation, discussion, context or full conclusions in the form of tables and text to describe data/information where this is not easily presented in tabular form] prior to submission to CNS Neuroscience & Therapeutics will not jeopardize full peer reviewed publication in the journal).
Research ethics. You will be asked during online submission to confirm that your study has been approved by relevant bodies (e.g. institutional review boards, research ethics committees) and that appropriate consent was obtained for studies involving human participants. Publication ethics. CNS Neuroscience & Therapeutics's author guidelines were prepared with reference to Best Practice Guidelines on Publication Ethics: a Publisher's Perspective (Graf C, Wager, E, Bowman A et al. Int J Clin Pract 2007;61[s152]:1-26).
Clinical trials - registration. Reports of clinical trials should include the clinical trial registration number and registry name at the end of the abstract.
Clinical trials - data posting. If trial data are posted online before submission and peer reviewed publication, provide the clinical trial results database number and database name at the end of your abstract.
Appendix (e.g. list of participating physicians). Optional. Will appear in print and online. Use an appendix immediately following references to list further details related to clinical studies like participating physicians, clinical and coordinating centers (which should be presented in the most concise form possible, i.e. not tabulated).
Supporting Information (e.g. OnlineExtra slideshows). Optional. Will only appear online. Should be submitted online during manuscript submission as 'Supplementary Files'. Supporting information is additional material to accompany your printed article online. Supporting information, slideshows or supporting data, should draw exclusively from or support material presented in your manuscript.
Tables. All tables should be mentioned in the text and individually numbered. Tables should be presented together and separated from the main text. They should be numbered in the order in which they are mentioned in the text, and each should have a short explanatory caption. Each table column should have a short heading. Any tables previously published should be submitted with the written consent of the copyright holder, an acknowledgement should be included in the caption, and the full reference included in the reference list.
Illustrations. For detailed information about preparing and submitting digital images, please register at the Wiley-Blackwell Author Services website and refer to the 'Author Resources' pages.
Illustrations will only be accepted if provided electronically (TIFF preferred; JPEG, GIF, EPS, PNG Microsoft PowerPoint, Microsoft Excel also acceptable); they should be professionally drawn, labeled and photographed; freehand lettering is not acceptable. Staining techniques and the magnification of micrographs should be stated, and arrows/abbreviations explained in the captions. If the subjects of photographs are identifiable, either their eyes should be masked or their written permission to use the photograph be submitted with the manuscript. Any information (including personal data) that could enable a patient to be identified should be removed.
All illustrations and figures should be mentioned in the text and individually numbered. Only those essential to the paper should be included. Illustrations and figures should be presented together and separated from the main text. They should be numbered in the order in which they are mentioned in the text, and each should have a short explanatory caption. Any illustrations and figures previously published should be submitted with the written consent of the copyright holder, an acknowledgement should be included in the caption, and the full reference included in the list. Illustrations may be reproduced in colour if essential to the article. A charge will be made for colour reproduction. If colour is required, a Colour Work Agreement Form must be completed and returned to the Editorial Office. Any article received with colour work will not be published until this form has been returned.
Measurements, abbreviations, drug names. Measurements should be given in the units in which they were made, but non-metric units must be accompanied by metric (SI) equivalents (exceptions: blood pressure in mmHg; haemoglobin in g/dl). Generic drug names should be used (drug brand names must not be used). If an acronym is used, the term for which it stands should be given in full at its first mention in the text, for example, anti-diuretic hormone (ADH).
References. Original textual matter quoted from other authors must have formal citation and be appropriately attributed and referenced. Authors should verify references against the original documents. References should be identified in the text using square brackets, and numbered and listed consecutively at the end of the paper in the order in which they are first cited in the text. The Vancouver style is used.
Journals. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997;95:320-333.
Books. Czarnetzki BM. Urticaria. Berlin: Springer, 1986.
Chapter in book. Clissold SP. Rhinitis. In: Barnes PJ, Mygind N, editors. Budesonide: clinical experience in asthma and rhinitis. Manchester: ADIS Press, 1988;51-64.
Copyright Assignment. Authors will be required to sign a Copyright Transfer Agreement (CTA) for all papers accepted for publication. Signature of the CTA is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. Please note that signature of the Copyright Transfer Agreement does not affect ownership of copyright in the material. (Government employees need to complete the Author Warranty sections, although copyright in such cases does not need to be assigned). After submission authors will retain the right to publish their paper in various medium/circumstances (please see the form for further details). To assist authors an appropriate form will be supplied by the editorial office. Alternatively, authors may like to download a copy of the form here
Early View - CNS Neuroscience and Therapeutics is covered by Wiley-Blackwell's Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. They have been fully reviewed, revised and edited for publication, and the authors' final corrections incorporated. Authors cannot make changes to their articles after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows each article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the articles.
OnlineOpen. OnlineOpen offers you the opportunity to ensure that your article is immediately and permanently made free to access online. If you want your paper to be OnlineOpen you need to complete the OnlineOpen Payment Form, as well as the standard Copyright Transfer Agreement (see above).
Proofs. Proofs must be returned within 3 days of receipt; late return may cause a delay in publication. Please check text, tables, legends, and references very carefully. Page proofs will be sent to authors, and it may be necessary to charge for alterations other than correction of printer's errors. Return proofs by fax (+44 131 226 3803) or return the pdf file with notes attached by e-mail (cns@wiley.com).
Offprints. Upon online publication, many journals give free access to the PDF file of the final, published article. In order to get access, you must register at our Wiley-Blackwell Author Services website. NOTE: Free access to the final PDF offprint or your article will be available via Author Services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.
EXPEDITED: Publish your clinical trials faster. EXPEDITED is the new priority publication service from CNS Neuroscience & Therapeutics exclusively for well conducted, well reported clinical trials. Priority peer review: 7 working days from online submission. Priority proofs: 7 working days from 'accept' decision. Priority online: 7 working days from proof approval to Early View publication. Priority print: 'Late Breaker' publication in the next print issue. Exclusively for clinical trials (interventional and observational studies). Contact us for more information (tgaston@wiley.com).
EXPEDITED instructions. Step #1 - Apply to the Editorial Office >1 week before online submission with a detailed abstract, list of authors, contributorship statement, clinical trial registration details, clinical trial data posting details (if available), complete CONSORT or STROBE checklist (note: at this stage replace page numbers on this checklist with the word 'Yes' to confirm that each CONSORT/STROBE recommendation has been followed), details of research funding and disclosures of potential conflicts of interest. Step #2 - We will confirm that we have received your application and whether we will expedite your peer review. If we accept your application for the EXPEDITED service, you will receive an invoice for $1,500 (non-refundable). Step #3 - Submit online as an 'EXPEDITED Clinical Trial'. Contact us for more information (tgaston@wiley.com).
EXPEDITED conditions. Standard CNS Neuroscience & Therapeutics peer review processes inform all editorial decisions (see our 'Editorial Policy' pages). The details contained in editorial recommendations and decisions about individual submitted papers are not linked to payment - the EXPEDITED service only aims to deliver these recommendations faster. Clinical trials submitted for consideration via the EXPEDITED service may be rejected. The EXPEDITED service charge is not refundable. Delivery of proofs in 7 working days from 'accept' decision is conditional on transmission of complete and correct copyright paperwork on or before date of 'accept' decision. Proofs will be delivered 7 working days from arrival of transmission of copyright paperwork if copyright paperwork is transmitted later than 'accept' decision. Contact us for more information (tgaston@wiley.com).
Editorial Board
Editors
Mark H. Pollack, MD
Roger Bullock, Swindon, UK
Editorial Board
James E. Barrett, Downingtown, PA
M. Flint Beal, New York, NY
Joseph Biederman, Boston, MA
Kathleen Brady, Charleston, SC
Jerry J. Buccafusco, Augusta, GA
Ross Bullock, Richmond, VA
Ramón Cacabelos, La Coruña, Spain
S. S. Chatterjee, Karlsruhe, Germany
Lee Cohen, Boston, MA
Marlene L. Cohen, Carmel, IN
Jack R. Cooper, New Haven, CT
Thilo Deckersbach, Boston, MA
Lindsay Devane, Charlston, SC
Giuseppe Di Giovanni, Msida, Malta
John F. Disterhoft, Chicago, IL
Bernardo Dubrovsky, Montreal, Quebec, Canada
John Dunlop, Princeton, NJ
Linda P. Dwoskin, Lexington, KY
Alan I. Faden, Washington, D.C.
Maurizio Fava, Boston, MA
Ezio Giacobini, Geneva, Switzerland
Don Goff, Boston, MA
Paul Greengard, New York, NY
Maria Hadjiconstantinou, Columbus, OH
Devon Hinton, Boston, MA
Elizabeth Hoge, Boston, MA
Heide Hörtnagl, Berlin, Germany
Dan Iosifescu, Boston, MA
Leslie L. Iversen, Oxford, UK
Leonard Kaczmarek, New Haven, CT
Sathapana Kongsamut, Bridgewater, NJ
Andrew Krystal, Durham, NC
George Kunos, Bethesda, MD
Stuart A. Lipton, La Jolla, CA
Paul Luiten, Haren, The Netherlands
Rafael Mechoulam, Jerusalem, Israel
Maurizio Memo, Brescia, Italy
John Stirling Meyer, Houston, TX
David Mischoulon, Boston, MA
Gordon Munro, Denmark
Toshiharu Nagatsu, Toyoake, Japan
Norton H. Neff, Columbus, OH
Andrew Nierenberg, Boston, MA
Patricia S Normand, Newton, MA
Michael Otto, Boston, MA
Antti Pertovaara, Helsinki, Finland
Daniele Piomelli, Irvine, CA
Mark Rapaport, Los Angeles, CA
Gregory Rose, Wallingford, CT
Jerrold Rosenbaum, Boston, MA
Tom Roth, Detroit, MI
Gary Sachs, Boston, MA
Darryle D. Schoepp, White House Station, NJ
John J. Schrogie, King of Prussia, PA
Teun Schuurman, Lelystad, The Netherlands
Naomi Simon, Boston, MA
Phil Skolnick, New York, NY
Jordan Smoller, Boton, MA
Murray Stein, San Diego, CA
Samuel J. Strada, Mobile, AL
Micahel Van Amerigen, Hamilton, Ontario
John Worthington, Boston, MA
Nancy R. Zahniser, Denver, CO
|
